Figure 2
From: Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies
BiAb-armed ATC specifically kill long term glioma cell lines. 2A: Non-irradiated or irradiated ATC were armed with the indicated amounts (ng/106 cells) of either EGFRBi (circles) or HER2Bi (triangles) and used as effector cells at an E:T of 5:1. The figure shows the results from one of two donors, with U118MG cells as targets. Both MTT and 51Cr assays were used as readouts. 2B: Shows the data for U87MG, U118MG, and U251MG cells using non-irradiated unarmed ATC or armed ATC at one arming dose of 50 ng for EGFRBi, HER2Bi and CD20Bi at E/T of 5:1. Both MTT and 51Cr assays were used as readouts. 2C: U87MG, U118MG, and U251MG cells were exposed overnight to the indicated effector cells at an E:T of 5:1 and residual viability determined by MTT assay. U87MG expresses only EGFR whereas U118MG and U251MG express both HER2/neu and EGFR. Data were analyzed by 1-way ANOVA: for all 3 glioma lines, overall p < 0.0001; for all 3 lines, unarmed vs. CD20Bi p value is non-significant (p > 0.05) (n.s.). 2C (lower panel): Shows the expression of EGFR and HER2 (blue) compared to isotype control (red), and plots for percent positive cells and mean fluorescence intensity (MFI). For U87MG, Unarmed vs. HER2Bi, p > 0.05 (n.s.); Unarmed vs. EGFRBi, p < 0.001 (***). For U118MG, Unarmed vs. HER2Bi and Unarmed vs. EGFRBi, p < 0.001 (***). For U251MG, Unarmed vs. HER2Bi and Unarmed vs. EGFRBi, p < 0.001 (***).